ABL Awarded NIH Contract to Fund up to $102M in Biologics Manufacturing and Characterization Services
Rockville, MD (August 1, 2012) – Advanced BioScience Laboratories, Inc. (ABL, Inc.) announced today the award of a contract to provide the NIH National Institute of Allergy and Infectious Diseases (NIAID) with preclinical development and cGMP manufacturing support for multiple vaccine and biologic products identified by NIAID Program staff. The contract has a funding potential of up to $102 million over 10 years, subject to availability of annual appropriations.
Under the contract titled, “Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases”, ABL will provide services from early feasibility studies through manufacture of Phase I/II material to more rapidly and efficiently close development and production gaps and increase the government’s response to emerging disease threats. ABL will also provide appropriate documentation and support for regulatory submissions for Phase I and II clinical testing.
Dr. Thomas VanCott, President and Chief Executive Officer of ABL commented, “We are extremely excited at the prospect of applying novel approaches, platforms and technologies in support of NIAID’s mission to develop candidates against a wide range of infectious diseases. This will be a great opportunity for ABL to develop vaccines and therapies targeting some of the most challenging agents including potential bioterror threats, drug-resistant pathogens, and emerging and re-emerging infectious diseases.”
This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201200005I.
Advanced BioScience Laboratories, Inc. (ABL) is a Maryland-based biomedical contract research and manufacturing organization dedicated to advancing the development of therapeutics, vaccines and other biologic products. ABL has extensive experience working with diverse organizations, including government and academic entities and commercial bio/pharmaceutical companies. Notable services include basic research, product design, process and assay development, preclinical in vivo and in vitro studies (including immunomonitoring), and Phase I/II cGMP biologics manufacturing. Since 2001 ABL has been a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally. For more information on ABL and our services, please visit our website at www.ablinc.com.